6 citations
,
August 2024 in “Biomacromolecules” This study introduces a novel in vitro model for clubfoot fibrosis to enable high-throughput drug screening and found that while the model increased collagen deposition, the antifibrotic drug minoxidil effectively inhibited the expression of collagen cross-linking enzymes.
6 citations
,
November 2023 in “Chinese Medicine” This study found that Xinyang Tablet may improve cardiac function in LPS-induced sepsis-induced myocardial dysfunction by modulating macrophage polarization and autophagy through affecting LncSICRNT1 and TRAF6 expression.
5 citations
,
June 2022 in “Biophysical Journal” This study used a probabilistic Boolean network model to explore hair follicle cell fate regulation and predicted that varying TGF-β levels, in coordination with BMP and TNF, can influence either apoptosis or cell proliferation during different follicle growth stages.
5 citations
,
November 2020 in “Forensic Science International Genetics” This study found that using trait prevalence-informed priors may improve the prediction accuracy of appearance traits in Bayesian models, but their application is limited by sparse knowledge on trait prevalence.
4 citations
,
June 2025 in “JMIR Formative Research” In this study, researchers reported no statistically significant association between hair cortisol levels and either perceived stress or objective neuroendocrine stress measures in a predominantly male participant group.
4 citations
,
September 2024 in “Skin Research and Technology” This study provides a comprehensive overview of the current state and emerging trends in SD (seborrheic dermatitis) research, aimed at aiding clinical practitioners and researchers in understanding valuable insights for decision-making and identifying future research directions.
4 citations
,
July 2024 in “Skin Research and Technology” Certain bacteria may influence alopecia areata risk, but skin bacteria don't mediate gut-skin effects.
4 citations
,
December 2023 in “Medicine” This study found that the genes MYLK and CALD1 were expressed at lower levels in bladder cancer and osteosarcoma tissues compared to normal tissues, and their expression levels appeared to correlate with poorer survival outcomes, suggesting they may be important in disease progression and prognosis.
4 citations
,
January 2019 in “Egyptian Journal of Dermatology and Venereology” This study suggests that androgenetic alopecia moderately affects quality of life, with women experiencing a higher impact and showing a greater willingness to pay for treatment than men.
3 citations
,
February 2025 in “Journal of Dermatological Treatment” This study found a positive association between clinically meaningful scalp hair regrowth and improvements in patient-reported outcomes, such as satisfaction and reduced psychosocial burden.
3 citations
,
January 2025 in “BMC Medical Informatics and Decision Making” This study suggests that novel diagnostic, preventive, and treatment approaches for autoimmune diseases like alopecia areata may be developed by identifying hub genes, and highlights the usefulness of machine learning and bioinformatics in finding new disease biomarkers.
3 citations
,
July 2024 in “Skin Research and Technology” Asthma may increase the risk of alopecia areata.
3 citations
,
September 2023 in “PeerJ Computer Science” This study introduced an innovative metric for assessing college students' mental health, incorporating temporal perception and a hybrid clustering algorithm, and found it achieved over 90% accuracy, outperforming existing methods in evaluating mental health during public health challenges.
3 citations
,
June 2023 in “Frontiers in Medicine” This study constructed a model using serum levels of BMP2, CD8A, PRF1, and XCL1 as a non-invasive biomarker to accurately predict recurrence in patients with alopecia areata.
2 citations
,
November 2025 in “Briefings in Bioinformatics” In this study, the researchers performed a comparative analysis of drug-target interaction data from multiple databases to refine drug repurposing strategies, revealing potential associations between drug characteristics and therapeutic groups, and predicting repositioning opportunities for FDA-approved drugs across major cancer types.
2 citations
,
July 2025 in “Biopolymers” This review explores the eggshell matrix as a potential sustainable and cost-effective alternative source for glycosaminoglycans, but highlights the need for further research to enhance extraction techniques and economic viability.
2 citations
,
July 2025 in “Journal of Ovarian Research” This study found that among women with PCOS, a bedtime after midnight was independently linked to higher androgen levels and decreased lean muscle mass.
2 citations
,
March 2025 in “Quantitative Imaging in Medicine and Surgery” In this study, patients with alopecia areata showed altered hypothalamic activity and connectivity, which may be linked to the neurophysiological basis of psychological stress experienced by these patients, as assessed by functional MRI and correlated with neuropsychological evaluations.
2 citations
,
July 2024 in “Skin Research and Technology” Copper may protect against alopecia areata, while certain inflammatory markers increase risk.
2 citations
,
February 2023 in “Urology” This study found that IsoPSA's ability to detect both any prostate cancer and clinically actionable prostate cancer remains unaffected by medications like 5-ARIs and α-blockers, which are commonly used to treat benign prostatic hyperplasia symptoms.
2 citations
,
December 2022 in “Metabolites” This study found that progesterone levels were suppressed in underweight anorexia nervosa patients compared to healthy controls, as measured through hair analysis, and did not increase during short-term weight restoration.
2 citations
,
July 2022 in “Cell Regeneration” This review discusses the complex interplay of factors controlling hair regeneration and highlights the potential for targeted clinical applications in various hair disorders, while reporting no new clinical results.
2 citations
,
January 2022 in “BioMed Research International” This study suggests that Gujian oral liquid may reduce osteoarthritis symptoms by regulating inflammation and catabolism through the TNF-α/NF-kappa B signaling pathway, as confirmed by both in vivo and in vitro experiments.
1 citations
,
January 2026 in “Science Advances” This study developed a 3D bioprinted skin model to mimic pemphigus vulgaris, providing a tool to study disease mechanisms and test targeted therapies by reproducing the architecture and pathogenic disruptions of native skin.
1 citations
,
January 2026 in “JAMA Network Open” This study found significant racial and ethnic disparities in the incidence and psychological impact of chemotherapy-related alopecia, with Asian women experiencing the greatest burden, highlighting the need for personalized and culturally sensitive care.
1 citations
,
April 2025 in “Behavioral Sciences” In a study of 435 undergraduate medical students, researchers found that rejection sensitivity was linked to increased loneliness and problematic internet use, with loneliness mediating this relationship and self-control moderating its impact, highlighting pathways and conditions that could inform interventions.
1 citations
,
January 2023 in “BMC Women's Health” This study reported a 3.86% prevalence of PCOS among tenth-grade schoolgirls in Guangzhou, with higher rates observed in obese girls compared to their lean counterparts.
1 citations
,
September 2021 in “Dermatologic Therapy” In this observational study, AC5 reduced hair loss in 89% of subjects with mild androgenic alopecia, and was well tolerated and appreciated by most participants.
1 citations
,
August 2018 in “Madridge journal of dermatology & research” This study observed that the Pilogics Hairegen device increased total hair count by 23.2% and terminal hair count by 21.1% in 289 patients with androgenetic alopecia after approximately 20 weeks of use, with no adverse effects reported.
March 2026 in “The Aging Male” This retrospective pharmacovigilance study reviewed adverse event reports from 2004 to 2025 for drugs treating benign prostatic hyperplasia, identifying distinct safety signals for α1-blockers, 5ARIs, and PDE5I, including some potential new adverse events that require further investigation.